TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, today announced the successful closure of a $3M Series B round designed to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages.
“This round of financing is significant for several reasons, but most notably, it enables us to explore the potential of our therapeutic’s highly differentiated mechanism of action in additional attractive corneal indications,” said Anil Asrani, President and CEO of TearSolutions. “Moreover, this funding allowed us to convert existing debt, strengthening the Company’s financial position as we look ahead.”
Learn more here.